Trial record 13 of 435 for:    hepatitis b | Open Studies

New Methods to Measure the Immune Response to Hepatitis B Vaccine

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2013 by University of Oxford
Sponsor:
Information provided by (Responsible Party):
University of Oxford
ClinicalTrials.gov Identifier:
NCT01821547
First received: March 18, 2013
Last updated: March 26, 2013
Last verified: March 2013
  Purpose

Hepatitis B vaccine is a safe and effective vaccine used widely throughout the world. Because of this it is a useful vaccine in which to develop new methods for studying immune responses. Measuring the immune response to vaccines helps us to understand how they work and whether they are likely to protect any individual against infection. For most vaccines we measure the immune system's production of antibody after a vaccine has been given. The investigators want to develop new methods that give a far more detailed picture of the antibody response to vaccines than has previously been possible. These methods will investigate the genetic instructions used by each antibody producing cell to make antibody. These methods have the potential to give new insights into the way vaccines work, which could be applied to studying vaccines and vaccine schedules in the future.


Condition Intervention Phase
Hepatitis B
Drug: Hepatitis B vaccine
Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Hepatitis B Immunisation: A Two-part Study Investigating Antigen Specific B Cell Receptors

Resource links provided by NLM:


Further study details as provided by University of Oxford:

Primary Outcome Measures:
  • Part 2- To assess B cell VH/L gene segment usage by HepB specific B cells during and following administration of a three dose course of HepB vaccine given at 0,1, 2 or 0, 1, 6 months. [ Time Frame: 0 and 7 days after the second immunisation, and 0, 7 and 40 days after the third immunisation ] [ Designated as safety issue: No ]
    HepB specific cells will be isolated using magnetic-activated cell sorting, and fluorescence-activated cell sorting. VH/L gene segments will be amplified by PCR, and DNA prepared for sequencing. Bioinformatic approaches will then be used to create frequency tables of the different V, D and J exons that comprise these gene segments.

  • Part 1- To validate B cell assays and assess the kinetics of HepB specific B cell subsets following administration of a booster dose of HepB vaccine given to previously immunised healthy adults. [ Time Frame: 0, 7, 14, 21 and 28 days after immunisation ] [ Designated as safety issue: No ]
    HepB specific B cell subsets will be identified using both ELISPOT and flow cytometry.


Secondary Outcome Measures:
  • Part 1 • To measure HepB surface antigen-specific antibody concentration following administration of a booster dose of HepB vaccine given to previously immunised healthy adults [ Time Frame: 0 and 28 days after immunisation ] [ Designated as safety issue: No ]
    Antibody concentrations will be determined from blood plasma using an ELISA

  • Part 1 • To assess B-cell receptor VH/L gene sequences used in HepB specific and non-antigen specific B-cells prior to and following administration of a booster dose of HepB vaccine given to previously immunised healthy adults [ Time Frame: 0, 7, 14, 21 and 28 days after immunisation ] [ Designated as safety issue: No ]
    VH/L gene segments will be amplified by PCR, and DNA prepared for sequencing. Bioinformatic approaches will then be used to create frequency tables of the different V, D and J exons that comprise these gene segments.

  • Part 1 • Comparison of B cell receptor VH/L gene segment usage as determined by two different next-generation sequencing methods (RNA-sequencing and 454). [ Time Frame: 0, 7, 14, 21 and 28 days after immunisation, as required ] [ Designated as safety issue: No ]
    Different sequencing protocols introduce different types of error and bias into the resulting sequence datasets. VH/L gene segments will sequenced using two different techniques. Bioinformatic approaches and descriptive analysis will then be used to compare the effects of the two different protocols. Frequency tables of the different V, D and J exons that comprise these gene segments will be generated, for comparison.

  • Part 1 • Collection of mRNA for subsequent gene expression analysis [ Time Frame: 0, 7, 14, 21 and 28 days after immunisation ] [ Designated as safety issue: No ]
  • Part 2 • To measure HepB specific plasma and memory B cell frequencies during and following administration of a three dose course of HepB vaccine given at 0, 1, 2 or 0, 1, 6 months. [ Time Frame: 0 and 7 days after the second immunisation, and 0, 7 and 40 days after the third immunisation ] [ Designated as safety issue: No ]
    HepB specific B cell subsets will be identified using both ELISPOT and flow cytometry.

  • Part 2 • To measure HepB surface antigen-specific antibody concentration during and following administration of a three dose course of HepB vaccine given at 0,1, 2 or 0, 1, 6 months. [ Time Frame: 0 days after the second immunisation, and 0 and 40 days after the third immunisation ] [ Designated as safety issue: No ]
    Antibody concentrations will be determined from blood plasma using an ELISA


Estimated Enrollment: 16
Study Start Date: March 2013
Estimated Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Hepatitis B vaccine
    Immunisation with HepB vaccine (HBvaxPRO, 10μg/ml, Sanofi Pastuer) via intramuscular injection into the non-dominant deltoid (part 1 only).
    Other Name: HBvaxPRO, 10μg/ml, Sanofi Pastuer
  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

All participants for both parts 1 and 2 must meet the following conditions in order to be enrolled:

  • Participant is willing and able to give informed consent for participation in the study
  • Healthy Male or Female, aged 18 - 60 years
  • No allergies to the vaccine or its excipients

Participants enrolling in Part 1 must also meet the following conditions:

  • Participant has previously received a primary immunisation course of HepB vaccine (3 primary doses). The 4th booster dose recommended after 12 months is not a requirement. There are a variety of possible recommended schedules, and any may have been used as long as the final vaccine (or booster vaccine) was given at least 12 months prior to the participant enrolling in the study.
  • Participant is willing to allow their General Practitioner to be notified, if appropriate, of participation in the study

Participants enrolling in Part 2 must also meet the following conditions Participant receiving HBvaxPro® (the usual vaccine given within the Occupational Health Department).

Exclusion Criteria:

The participant may not enter either study if ANY of the following apply:

  • Have any known or suspected impairment or alteration of immune function, resulting from, for example:

    • Congenital or acquired immunodeficiency (including IgA deficiency)
    • Human Immunodeficiency Virus infection or symptoms/signs suggestive of an HIV-associated condition
    • Autoimmune disease
    • Receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 12 months or long-term systemic corticosteroid therapy.
    • Chronic illness that could interfere with immunological function or donation of the required volumes of blood (e.g. cardiac or renal disease, diabetes, or auto-immune disorders).
  • Receipt of a HepB booster vaccine within the past 12 months.
  • Prior history of anaphylactic reaction to a previous dose of a Hepatitis B containing vaccine or known hypersensitivity to any vaccine component;
  • Receipt of blood, blood products, or plasma derivatives within the past 3 months.
  • Total blood donation greater than 50 ml within the past 3 months.
  • Thrombocytopenia or any bleeding disorder.
  • Pregnancy as confirmed by a positive pregnancy test, or currently breastfeeding.
  • Receipt of a live vaccine within 4 weeks prior to vaccination or a killed vaccine within 7 days prior to vaccination.
  • Plan to receive any vaccine other than the study vaccine within 4 weeks following vaccination.
  • Enrolled in another study, which, in the opinion of the investigator, could compromise the integrity of either study being conducted.
  • A member of staff on the delegation log
  • According to the TOPS database, have recently taken part in a significant number of other studies, which, in the opinion of the investigator, warrant exclusion from further studies.
  • Participant is a known non-responder to the HepB vaccine
  • Have any condition, which, in the opinion of the investigator, might interfere with the evaluation of the study objectives.
  • Unable to understand English, or what will be required from them during the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01821547

Contacts
Contact: Dominic Kelly dominic.kelly@paediatrics.ox.ac.uk

Locations
United Kingdom
Centre for Clinical Vaccinology & Tropical Medicine (CCVTM) Recruiting
Oxford, Oxfordshire, United Kingdom, OX3 7LE
Contact: Richard Sewell    01865 857490    richard.sewell@paediatrics.ox.ac.uk   
Sponsors and Collaborators
University of Oxford
Investigators
Principal Investigator: Dominic Kelly Oxford Vaccine Group
  More Information

No publications provided

Responsible Party: University of Oxford
ClinicalTrials.gov Identifier: NCT01821547     History of Changes
Other Study ID Numbers: OVG 2012/09
Study First Received: March 18, 2013
Last Updated: March 26, 2013
Health Authority: United Kingdom: Research Ethics Committee

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis B
Hepatitis, Viral, Human
Liver Diseases
Digestive System Diseases
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Hepadnaviridae Infections
DNA Virus Infections

ClinicalTrials.gov processed this record on September 18, 2014